Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress

  1. Jianjun Gao,
  2. Xiaoping Liu, and
  3. Basil Rigas*
  1. Division of Cancer Prevention, Department of Medicine, Stony Brook University, Stony Brook, NY 11794-5200
  1. Edited by Louis J. Ignarro, University of California School of Medicine, Los Angeles, CA (received for review August 19, 2005)

Abstract

Nitric oxide-donating aspirin (NO-ASA) is a promising chemoprevention agent against colon cancer and other cancers. It consists of traditional ASA to which a NO-releasing moiety is bound through a spacer. NO-ASA inhibits colon cancer cell growth several hundred times more potently than does ASA. In Min mice, NO-ASA inhibited intestinal carcinogenesis without affecting cell proliferation. Thus, we examined whether NO-ASA's most important cell kinetic effect is the induction of apoptosis. After confirming induction of apoptosis in Min mice, we studied the underlying mechanism in human colon adenocarcinoma cells. NO-ASA's spacer formed a conjugate with glutathione, depleting glutathione stores. This induced oxidative stress (increased intracellular levels of peroxides and Formula) leads to apoptosis by activating the intrinsic apoptosis pathway. NO-ASA disrupted adherens junctions by inducing cleavage of β- and γ-catenin, resulting in cell detachment. NO-ASA inhibited Wnt signaling by a dual mechanism: at low concentrations it blocked the formation of β-catenin/Tcf complexes (dominant mechanism), and at higher concentrations it also cleaved β-catenin. These findings provide a mechanism of action by a potent chemopreventive agent, underscore the significance of these pathways in regulating cell death in the context of cancer chemoprevention, and present a paradigm for developing agents with enhanced cancer cell growth inhibitory properties.

Footnotes

  • * To whom correspondence should be addressed. E-mail: basil.rigas{at}sunysb.edu.

  • Author contributions: J.G. and B.R. designed research; J.G. and X.L. performed research; J.G., X.L., and B.R. analyzed data; and J.G. and B.R. wrote the paper

  • Conflict of interest statement: No conflicts declared.

  • This paper was submitted directly (Track II) to the PNAS office.

  • Abbreviations: ASA, aspirin; NO-ASA, NO-donating aspirin; DEVD-FMK, Asp-Glu-Val-Asp fluoromethyl ketone; Z-VAD-FMK, benzyloxycarbonyl-Val-Ala-Asp-FMK; DHE, dihydroethidium; H2DCFDA, 2′,7′-dichlorofluorescine diacetate; GSH, glutathione; ROS, reactive oxygen species; NAC, N-acetylcysteine; PI, propidium iodide; BSO, dl-buthionine (S,R)-sulfoximine.

« Previous | Next Article »Table of Contents